Hu Q - Search Results

1

Erratum: Targeting BRD4 prevents acute gouty arthritis by regulating pyroptosis: Erratum.

Hao K, Jiang W, Zhou M, Li H, Chen Y, Jiang F, Hu Q. Hao K, et al. Among authors: hu q. Int J Biol Sci. 2025 Jan 1;21(2):473-474. doi: 10.7150/ijbs.107312. eCollection 2025. Int J Biol Sci. 2025. PMID: 39781448 Free PMC article.

2

Targeting BRD4 prevents acute gouty arthritis by regulating pyroptosis.

Hao K, Jiang W, Zhou M, Li H, Chen Y, Jiang F, Hu Q. Hao K, et al. Among authors: hu q. Int J Biol Sci. 2020 Oct 17;16(16):3163-3173. doi: 10.7150/ijbs.46153. eCollection 2020. Int J Biol Sci. 2020. PMID: 33162822 Free PMC article.

3

P2Y₁₄ receptor has a critical role in acute gouty arthritis by regulating pyroptosis of macrophages.

Li H, Jiang W, Ye S, Zhou M, Liu C, Yang X, Hao K, Hu Q. Li H, et al. Among authors: hu q. Cell Death Dis. 2020 May 26;11(5):394. doi: 10.1038/s41419-020-2609-7. Cell Death Dis. 2020. PMID: 32457291 Free PMC article.

4

Silencing of Gasdermin D by siRNA-Loaded PEI-Chol Lipopolymers Potently Relieves Acute Gouty Arthritis through Inhibiting Pyroptosis.

Ye SM, Zhou MZ, Jiang WJ, Liu CX, Zhou ZW, Sun MJ, Hu QH. Ye SM, et al. Mol Pharm. 2021 Feb 1;18(2):667-678. doi: 10.1021/acs.molpharmaceut.0c00229. Epub 2020 Jul 6. Mol Pharm. 2021. PMID: 32579365

5

HQL6 serves as a novel P2Y₁₄ receptor antagonist to ameliorate acute gouty arthritis through inhibiting macrophage pyroptosis.

Zhou M, Liu C, Guo Y, Qian J, Wang Y, Zhang Z, Hao K, Jiang C, Hu Q. Zhou M, et al. Among authors: hu q. Int Immunopharmacol. 2023 Jan;114:109507. doi: 10.1016/j.intimp.2022.109507. Epub 2022 Nov 30. Int Immunopharmacol. 2023. PMID: 36462336

6

Design, synthesis and anti-inflammatory evaluation of 3-amide benzoic acid derivatives as novel P2Y₁₄ receptor antagonists.

Zhang Z, Hao K, Li H, Lu R, Liu C, Zhou M, Li B, Meng Z, Hu Q, Jiang C. Zhang Z, et al. Among authors: hu q. Eur J Med Chem. 2019 Nov 1;181:111564. doi: 10.1016/j.ejmech.2019.111564. Epub 2019 Jul 26. Eur J Med Chem. 2019. PMID: 31376563

7

Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis.

Jiang F, Hu Q, Zhang Z, Li H, Li H, Zhang D, Li H, Ma Y, Xu J, Chen H, Cui Y, Zhi Y, Zhang Y, Xu J, Zhu J, Lu T, Chen Y. Jiang F, et al. Among authors: hu q. J Med Chem. 2019 Dec 26;62(24):11080-11107. doi: 10.1021/acs.jmedchem.9b01010. Epub 2019 Dec 13. J Med Chem. 2019. PMID: 31789032

8

GPR105-Targeted Therapy Promotes Gout Resolution as a Switch Between NETosis and Apoptosis of Neutrophils.

Liu C, Zhou M, Jiang W, Ye S, Tian S, Jiang C, Hao K, Li H, Hu Q. Liu C, et al. Among authors: hu q. Front Immunol. 2022 Mar 30;13:870183. doi: 10.3389/fimmu.2022.870183. eCollection 2022. Front Immunol. 2022. PMID: 35432308 Free PMC article.

9

(E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1.

Hu Q, Zhou M, Zhu H, Lu G, Zheng D, Li H, Hao K. Hu Q, et al. Biomed Pharmacother. 2017 Feb;86:88-94. doi: 10.1016/j.biopha.2016.12.002. Epub 2016 Dec 9. Biomed Pharmacother. 2017. PMID: 27951420

10

4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3.

Zhou M, Li S, Song L, Hu Q, Liu W. Zhou M, et al. Among authors: hu q. Phytomedicine. 2018 Mar 15;42:9-17. doi: 10.1016/j.phymed.2018.03.007. Epub 2018 Mar 6. Phytomedicine. 2018. PMID: 29655702

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,251 results

Search Page

Filters